Emerging Science Session

Event Time: Tuesday April 25, 2017 5:45 pm to 7:15 pm
Topic(s): Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG)
Director(s):
Description: A special session emphasizing ongoing neuroscience research of an extraordinary nature, which warrants expedited presentation. Key aspects of the research must have taken place after October 24, 2016.
Completion Message:
CME Credits: 1.5
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
5:45 PM 001 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial David Dodick, MD, FAAN
Disclosure:
Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Allergan, Amgen, Alder, Dr Reddy’s, Merck, Dr Reddy’s, Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, GBS, Colucid, Zosano, Laydenburg Thalmann, Biocentric, Biohaven, Magellan, Pfizer (Japan), Charleston Laboratories. Royalties: Oxford University Press and Cambridge University Press (Book Royalty). Dr. Dodick has received personal compensation in an editorial capacity from Uptodate, Chameleon Communications, Medscape, WebMD, Academy for Continued Healthcare Learning, Haymarket Medical Education, Miller Medical Communications, Global Scientific Communications, HealthLogix, Academy for Continued Healthcare Learning, Meeting LogiX, Health LogiX, Dr. Dodick has received compensation for serving on the Board of Directors. Dr. Dodick holds stock and/or stock options in Nocira and Second Opinion.

5:48 PM 002 Non-invasive Vagus Nerve Stimulation for the Acute Treatment of Episodic and Chronic Cluster Headache: Findings From the Randomized, Double-blind, Sham-Controlled ACT2 Study Peter Goadsby, MD, PhD
Disclosure:
Dr. Goadsby has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Electrocore, Eli-Lilly, eNeura, Novartis, and Teva. Dr. Goadsby has received personal compensation in an editorial capacity for Journal Watch, Up-to-Date, Oxford University Press, Massachusetts Medical Society, and Walters Kluwer. Dr. Goadsby has received compensation for serving on the Board of Directors of Trigemina Inc. Dr. Goadsby has received research support from Amgen.

5:51 PM 003 Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized medical treatment Regina Katzenschlager
Disclosure:

5:54 PM 004 Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial Chadwick Christine, MD
Disclosure:
Research support from Voyager Therapeutics.

5:57 PM 005 Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose Phase 2 study Mark Stacy, MD, FAAN
Disclosure:
Dr. Stacy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advisory board attendee for Neurocrine Biosciences, Inc..

6:00 PM 006 RESULTS OF A PHASE 1 STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN ALZHEIMER’S DISEASE AND PSP Hana Florian
Disclosure:

6:03 PM 007 Sustained seizure reduction with adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC): Long-term results from the phase 3 EXIST-3 study David Franz, MD
Disclosure:
Dr. Franz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Franz has received research support from Novartis.

6:06 PM 008 Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3) Anup Patel, MD
Disclosure:
Dr. Patel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel has received personal compensation in an editorial capacity for Webinar Development: American Academy of Neurology. Dr. Patel has received research support from Greenwich Biosciences, LivaNova, Upsher-Smith.

6:09 PM 009 Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study Richard Finkel, MD
Disclosure:
Dr. Finkel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting fees and travel costs from AveXis, Biogen, Catabasis, Ionis, Mitobridge, and Summit. Dr. Finkel has received research support from My institution received research support to perform clinical trials from Biogen, BMS, Catabasis, Cytokinetics, Ionis, Lilly, ReveraGen, Sarepta, and Summit.

6:12 PM 010 Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the PATH Study Ivo Van Schaik, MD
Disclosure:
Dr. Van Schaik has received personal compensation in an editorial capacity for Cochrane Neuromuscular Disease Group. Dr. Van Schaik has received research support from CSL Behring; Baxter.

6:15 PM 011 Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR1940-C-004) John Vissing, MD
Disclosure:
I have served on Advisory boards of Alexion Pharmaceuticals and Ultragenyx.

6:18 PM 012 Dual Responder Analyses of Both Muscle Strength and Activities of Daily Living, Eculizumab Versus Placebo, in Refractory Generalized Myasthenia Gravis (gMG) Patients: Results from the REGAIN Study James Howard, MD, FAAN
Disclosure:
Dr. Howard has nothing to disclose.

6:21 PM 013 Comparison of protein-coding and long, non-coding RNA gene expression signatures to classify multiple sclerosis Charles Spurlock, PhD
Disclosure:
Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock is co-founder and CEO of IQuity, Inc. IQuity has licensed technology from Vanderbilt University Medical Center where Dr. Spurlock serves on the faculty. . Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock has received research support at Vanderbilt University Medical Center from Pfizer to support basic science research. .

6:24 PM 014 A ‘surface-in’ gradient of thalamic damage is an early and disease-specific process in pediatric-onset multiple sclerosis Giulia Fadda, MD
Disclosure:
Dr. Fadda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Atara Biotherapeutics INC.

Register Now

Related Courses